EUCTR2012-005486-13-GB进行中（未招募）1 期
A Phase II Randomized Study to Compare Anti-VEGF Agents in the Treatment of Diabetic Macular Edema (CADME) - A Study to Compare Anti-VEGF Agents in the Treatment of DME (CADME)
The National Eye Institute0 个研究点目标入组 60 人开始时间: 2013年2月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •(1) Participant is 18 years of age or older. (2) Participant has a diagnosis of diabetic mellitus (type 1 or type 2). Any one of the following will be considered to be sufficient evidence that diabetes is present: Current regular use of insulin for the treatment of diabetes; Current regular use of oral anti-hyperglycemia agents for the treatment of diabetes; Documented diabetes by ADA and/or WHO criteria. (3) Participant must understand and sign the protocol’s informed consent document. (4) Female participants of childbearing potential (see Appendix 1 for definition) must not be pregnant or breast-feeding and must have a negative pregnancy test at screening and must agree to pregnancy testing throughout the study. (5) Female participants of childbearing potential (see Appendix 1) and male participants able to father children must have (or have a partner who has) had a hysterectomy or vasectomy, be completely abstinent from intercourse or must agree to practice two acceptable methods of contraception throughout the course of the study and for four weeks after their last injection. Acceptable methods of contraception include: Hormonal contraception (i.e., birth control pills, injected hormones, dermal patch or vaginal ring); Intrauterine device; Barrier methods (i.e., diaphragm, condom) with spermicide; or Tubal ligation. (6) Participant has at least one eye that meets all of the following criteria: eye has a BCVA ETDRS score between 20/32 and 20/400; eye has definite retinal thickening or cystic changes due to DME based on clinical exam involving the center of the macula that is not refractory to further therapy as based on the investigator’s clinical judgment; eye has retinal thickness in the central subfield on baseline OCT measurement = 330 microns, as measured by Cirrus™ OCT; eye has clear ocular media and adequate pupillary dilation sufficient for adequate fundus photographs; eye does not have macular edema considered to be due to a cause other than diabetes (an eye is not eligible if: the macular edema is considered to be related to cataract extraction, or clinical examination and/or OCT suggest that vitreoretinal interface disease (e.g., a taut posterior hyaloid or epiretinal membrane) is the primary cause of the macular edema); eye does not have an ocular condition present such that, in the opinion of the investigator, visual acuity would not improve from resolution of macular edema (e.g., foveal atrophy, pigmentary changes, dense subfoveal hard exudates, non-retinal condition); eye does not have an ocular condition present (other than DR) that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the course of the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, Irvine-Gass Syndrome, etc.); eye does not have a history of panretinal scatter photocoagulation (PRP) within three months prior to enrollment; eye does not have a history of prior pars plana vitrectomy prior to enrollment; eye does not have a history of major ocular surgery (including cataract extraction, scleral buckle, any intraocular surgery, etc.) within three months prior to enrollment; eye does not have a history of Yttrium-Aluminum-Garnet (YAG) capsulotomy performed within two months prior to enrollment; eye has not had laser photocoagulation treatment, or received intravitreal or periocular steroids within three months prior to enrollment; eye does not have a history of int
排除标准
- •(1) Participant is in another investigational study and actively receiving investigational product for DME. (2) Participant has a known hypersensitivity to sodium fluorescein dye. (3) Participant has a condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure and glycemic control). (4) Participant has a history of chronic renal failure requiring dialysis or kidney transplant. (5)Participant has a history of liver failure. (6) Participant has a known hypersensitivity to bevacizumab, ranibizumab or any of their components. (7) Participant has a blood pressure of > 180/110 (systolic above 180 OR diastolic above 110). If blood pressure is brought below 180/110 by anti-hypertensive treatment, a patient can become eligible. (8) Participant has a history of treatment with oral steroids ( = 10 mg of prednisone daily or equivalent) within three months prior to enrollment. Non-ocular depot and inhaled steroid treatments will not exclude a participant. (9) Participant has a history of treatment with systemic anti-VEGF agents within four weeks prior to enrollment.
研究者
相似试验
已完成
不适用
Clinical study in new protocol of anti-VEGF agents for macular edema with retinal vein occlusion and in relation between the protocol and cytokinesRetinal Vein OcclusionJPRN-UMIN000030311Tokyo medical university100
尚未招募
不适用
Evaluation of the responsiveness of anti-VEGF treatment in DMEdiabetic retinopathy (DR)NL-OMON29053GSMS70
已完成
2 期
Randomized phase II study of clinical effect of Vessel Sealing System (Ligasure) for open gastrectomy.Gastric cancerJPRN-UMIN000003300Multicenter Clinical Study Group of Osaka(MCSGO)130
进行中（未招募）
1 期
A randomized phase 2 study of the anti-angiogenesis agent AG-013736 in combination with gemcitabine in patients with chemotherapy-naïve advanced pancreatic cancer preceded by a phase 1 portion - N/ATreatment of patients with chemotherapy-naïve, locally advanced or metastatic epithelial cancer of the exocrine pancreasMedDRA version: 5.1Level: LLTClassification code 10033604EUCTR2005-000053-30-ESPfizer, S.A.102
进行中（未招募）
不适用
A randomized phase 2 study of the anti-angiogenesis agent AG-013736 in combination with gemcitabine in patients with chemotherapy-naïve advanced pancreatic cancer preceded by a phase 1 portioTreatment of patients with chemotherapy-naïve, locally advanced or metastatic epithelial cancer of the exocrine pancreasMedDRA version: 5.1Level: LLTClassification code 10033604EUCTR2005-000053-30-BEPfizer Inc. - La Jolla laboratories102